Bavarian Nordic A/S banner

Intrinsic Value

The intrinsic value of Bavarian Nordic A/S (BV3) under the Base Case is 22.67 EUR per share. Compared with the current market price of 27.98 EUR, the stock appears Overvalued by 19% .

The intrinsic value is the average of valuations using the DCF method and multiples.

Do our valuations actually work? See backtest results .

BV3 Intrinsic Value
€22.67
Overvaluation 19%
Intrinsic Value
Price €27.98
B

BV3 is valued in line with its history. A premium of this size has been typical over the past 5 years.

Monitor BV3
Get notified when the price drops
Track Buy Zone
20% below Intrinsic Value €18.13
Get notified when the price drops into your buy zone
Current Price €27.98
Intrinsic Value €22.67
Margin of Safety 20% €18.13
Or choose another margin of safety
0% below Intrinsic Value
10% below Intrinsic Value
30% below Intrinsic Value
40% below Intrinsic Value
50% below Intrinsic Value
Custom
Alternatives to BV3

Fundamental Analysis

What Bavarian Nordic A/S Does

Biotechnology Health Care

Bavarian Nordic is a vaccine company that develops, makes, and sells vaccines for infectious diseases. Its best-known products are vaccines for smallpox and mpox, rabies, and tick-borne encephalitis, along with a few other travel and specialty vaccines. It also works on vaccine candidates for other diseases and immune-related medicines, but its core business is finished vaccines rather than general drug development.

Headquarters
Denmark DK
Employees
1 861
IPO date
Nov 2, 1998
Read the full company overview
View Company Overview
Financials
Efficiency

Earnings Waterfall
Bavarian Nordic A/S

Wall St Price Targets

Capital Returns

Competitive Landscape

What is the Intrinsic Value of one BV3 stock?

The intrinsic value for Bavarian Nordic A/S (BV3) under the Base Case is 22.67 EUR.

Is BV3 stock undervalued or overvalued?

Compared with the current market price of 27.98 EUR, the stock appears Overvalued by 19% .

Back to Top